Apogee Therapeutics

APGE

Market cap $2.2B

Overview Fund Activity

36.88 USD

-0.39

1.05%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

38.75

+1.87

5.07%

1 day

-1.05%

5 days

-2.92%

1 month

0.49%

3 months

-11.9%

6 months

-4.28%

Year to date

-21.78%

1 year

-25.03%

5 years

73.72%

10 years

73.72%

About: Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Employees: 196

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

73% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 22

25% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 5 (+1) [Q2]

9% more capital invested

Capital invested by funds: $2.3B [Q1] → $2.51B (+$210M) [Q2]

8% more funds holding

Funds holding: 167 [Q1] → 181 (+14) [Q2]

8.01% less ownership

Funds ownership: 133.61% [Q1] → 125.6% (-8.01%) [Q2]

15% less repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 65

46% less call options, than puts

Call options by funds: $18.5M | Put options by funds: $34.4M

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$87

136% upside

Avg. target

$102

175% upside

High target

$116

215% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

B of A Securities Tim Anderson	$87	Buy Maintained	28 Aug 2025
Guggenheim Seamus Fernandez	$116	Buy Reiterated	2 Jul 2025

See Analyst Rankings

Financial journalist opinion

Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress

SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced data from the Phase 2 APEX trial of APG777 for moderate-to-severe atopic dermatitis was accepted for a late-breaker oral presentation at the upcoming EADV Congress 2025, to be held in Paris, France from September 17-20, 2025. The Company will also present multiple poster presentations highlighting APG777's best-in-class potential including data supporting its combination strategy.

Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress

Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum

SAN FRANCISCO and BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on Tuesday, September 16, 2025, at 11:30 a.m. E.T.

Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results

Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results

Zacks Investment Research

Wall Street Analysts See a 152.41% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 152.4% in Apogee Therapeutics Inc. (APGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 152.41% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?

Apogee Therapeutics: Funding Supports Best-In-Class Ambitions In Atopic Dermatitis

Apogee Therapeutics, Inc.'s APG777 shows best-in-class week-16 efficacy and quarterly/semi-annual dosing potential. In my view, this could give this drug candidate a great competitive profile. In fact, APG777 could potentially disrupt the massive AT market, which is currently dominated by Dupixent. APGE's Phase 2 trial, called APEX Part A, exceeded its targets. We also have to wait until 1H2026 for its maintenance data. Part B efficacy data is due by mid-2026.

Apogee Therapeutics: Funding Supports Best-In-Class Ambitions In Atopic Dermatitis

Proactive Investors

Apogee Therapeutics reports positive Phase 2 results for atopic dermatitis drug

Apogee Therapeutics (NASDAQ:APGE) shares fell almost 15% despite the release of positive Phase 2 APEX trial results for APG777, its anti-IL-13 antibody for moderate-to-severe atopic dermatitis. The trial met its primary endpoint with a 71% reduction in Eczema Area Severity Index (EASI) score at Week 16, versus 33.8% for placebo.

Apogee Therapeutics reports positive Phase 2 results for atopic dermatitis drug

Investors Business Daily

Apogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker.

Apogee Therapeutics shares crumbled Monday despite promising results for what could become a quarterly or twice-yearly shot to control eczema.

Apogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker.

Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis

APEX Part A met all primary and key secondary endpoints and exceeded trial objectives, including 7 1.0% decrease from baseline in EASI at Week 16

Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced it will report Part A 16-week data from the Phase 2 APEX trial of APG777 on Monday, July 7, 2025. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m.

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

Zacks Investment Research

Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 129.1% in Apogee Therapeutics Inc. (APGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?

See News Rankings

Charts implemented using Lightweight Charts™